[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-head-and-neck-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-head-and-neck-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100565408","phase-3-palliative-steroeotactic-body-radiotherapy-vs-palliative-standard-radiotherapy-in-patients-with-advanced-head-and-neck-cancer-100565408",false,"NCT06641791","Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer","A Phase III Randomized Controlled Trial Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer","Inclusion Criteria:\n\n* Histologically confirmed mucosal squamous cell carcinoma (SCC) of the head and neck arising from at least one of the following sites: oro\u002Fhypopharynx, oral cavity, supraglottic larynx, maxillary sinus, nasal cavity, or unknown primary\n* Stages TX or T0-T4\u002FN0-N3\n* Must be considered unfit for curative intent RT as determined by the treating oncologist(s)\n* Geriatric 8 score \\\u003C14\n* Patient must be ≥18 years of age\n* Staging CT or MRI of the head and neck within 8 weeks prior to randomization\n* Chest CT or x-ray. PET CT is permitted if CT is of diagnostic quality.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3\n* Participants of childbearing potential must have agreed to use a highly effective contraceptive method during protocol therapy.\n* Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational treatment are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with nasopharyngeal carcinoma.\n* Prior systemic therapy (including immunotherapy).\n* Prior radiotherapy to the head and neck excluding superficial radiotherapy for head and neck skin cancer that does not overlap with current protocol treatment.\n* Prior head and neck cancer excluding skin cancer.\n* Patients with tumour locations\u002Fat risk of SBRT toxicity, including glottic\u002Fsubglottic larynx, T4 hypopharynx, post-cricoid, cervical esophagus, circumferential pharyngeal involvement, extension\u002Fproximity to brain\u002Foptic structures, any single tumour mass \\>8 cm (in one dimension).\n* \\> 2 nodal levels (Level 1a\u002Fb not counted); retropharyngeal lymph nodes (where the closest edge is \\\u003C 2cm from the closest edge of CTV (primary or nodal) will not be considered as a different level). Note: a single lymph node mass that spans 2 levels will be considered as 1 level.\n* Gross tumour poorly visualized on CT\u002FMRI.\n* Definitive radiological or clinically evident distant metastases.\n* Scleroderma\u002FCREST syndrome.","ALL","18 Years",{"count":19,"type":20},196,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?",[26],"Advanced Head and Neck Cancer","RECRUITING","2026-06-08",{"date":30,"type":31},"2026-06-09","ACTUAL",{"date":33,"type":31},"2025-04-07",{"date":35,"type":20},"2031-06-01",{"name":37,"class":38},"Canadian Cancer Trials Group","NETWORK",8,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100620708","phase-2-cyclophosphamide-and-etoposide-as-a-metronomic-therapy-in-advanced-head-and-neck-squamous-cell-cancer-100620708","NCT07361133","Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer","Cyclophosphamide and Etoposide as a Promising Metronomic Therapy in Advanced Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Adult participants, age = or \\> 18 years\n* Participants with recurrent head and neck squamous cell carcinoma after failure on first line chemotherapy.\n* Participants with advanced progressed, resistant, metastatic head and neck squamous cell carcinoma.\n\nExclusion Criteria:\n\n* Adjuvant and Neoadjuvant head and neck squamous cell carcinoma patients.",{"count":48,"type":20},120,[50],"PHASE2","The goal of this clinical trial is to learn if drugs as cyclophosphamide (C) and etoposide (E) work to treat advanced head and neck cancer in adults. It will also learn about the safety of both drugs. The main questions it aims to answer are:\n\nDo drugs C and E work to treat advanced head and neck cancer, after failure on first line chemotherapy? What medical problems do participants have when taking drugs C and E? Researchers will compare drugs C and E in combination to a placebo (a look-alike substance that contains no drug) to see if these 2 drugs works to treat advanced head and neck cancer.\n\nParticipants will:\n\nTake drug C every 3 weeks and drug E every 4 weeks or a placebo every week for 6 months.\n\nVisit the clinic once every 3 weeks for checkups and tests. Keep a diary of their symptoms.",[53,26],"Squamous Cell Carcinoma",[55,56,57,58,59,60],"Cyclophosphamide","Etoposide","Head and neck squamous cell carcinoma","Metastatic","Advanced","Recurrent","NOT_YET_RECRUITING","2026-04-13",{"date":64,"type":31},"2026-04-16",{"date":66,"type":20},"2026-04",{"date":68,"type":20},"2026-09",{"name":70,"class":71},"National Cancer Institute, Egypt","OTHER",1]